Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPC- and CHX-based antiviral mouthwash for elimination of SARS-CoV-2 from saliva
DRKS00026711Phase 4Completed
- Sponsor
- Poliklinik für Zahnärztliche Chirurgie und Aufnahme (UKD)
- Start
- Oct 2021
- Modality
- Small Molecules, Conventional Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of cetylpyridinium chloride and chlorhexidine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Poliklinik für Zahnärztliche Chirurgie und Aufnahme (UKD). Primary endpoint: Reduction/elimination of SARS-CoV-2 from saliva. Started Oct 2021; status: completed.
02
Drugs
cetylpyridinium chloridechlorhexidine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on DRKS00026711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00026711.